Roche announces positive pivotal Phase II results for Hedgehog Pathway Inhibitor
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results in people with advanced basal cell carcinoma (aBCC), a particularly severe and debilitating form of skin cancer.
Phase III Study of Investigational Compound Ipilimumab Achieves Primary Endpoint
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) today announced that a clinical trial - known as study 024 - of its investigational compound ipilimumab has met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma.
Novartis receives European Commission approval for Gilenya®
- Details
- Category: Novartis
The European Commission has granted Novartis approval for Gilenya® (fingolimod) 0.5 mg daily as a disease modifying therapy in patients with highly active relapsing-remitting multiple sclerosis (RRMS) despite treatment with beta interferon, or in patients with rapidly evolving severe RRMS.
GSK supports recovery efforts to help those affected by the Japan earthquake
- Details
- Category: GlaxoSmithKline
In response to events in Japan as a result of the Tohoku Kanto Earthquake and tsunami that devastated Japan's north east coastline region, GlaxoSmithKline (GSK) is supporting the ongoing relief efforts by working with the Japanese authorities,
Novartis committed to provide equivalent of more than USD 3 million in relief aid to Japan earthquake victims
- Details
- Category: Novartis
Novartis has committed to providing the equivalent of over USD 3 million in immediate relief aid to the victims of the recent earthquake in Japan.
MorphoSys Signs Manufacturing Agreement with Boehringer Ingelheim
- Details
- Category: Boehringer Ingelheim
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and Boehringer Ingelheim announced the signing of a biopharmaceutical manufacturing agreement for therapeutic antibodies.
NAFE Names Lilly to Top 50 Companies for Executive Women
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) has been named to the 2011 NAFE Top 50 Companies for Executive Women by the National Association for Female Executives (NAFE).
More Pharma News ...
- GSK announces positive topline results of Phase lll study of IPX066 in advanced Parkinson's disease
- Amgen Donates $1 Million to Help Japanese Disaster Victims
- Abbott Supports Relief Efforts in Japan
- OncoTrack: A new International consortium launches project in the area of genomic cancer diagnostics
- GlaxoSmithKline and Human Genome Sciences announce FDA approval of Benlysta® (belimumab)
- FDA accepts new drug application for investigational compound Dapagliflozin
- Genzyme Board Unanimously Recommends that Shareholders Accept sanofi-aventis Revised Offer and Tender Shares